DOCSLIB.ORG

Defeating Meningitis by 2030: Baseline Situation Analysis 6.3 Implementation Status

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Defeating Meningitis by 2030: Baseline Situation Analysis 6.3 Implementation Status DEFEATING MENINGITIS BY 2030: baseline situation analysis 20 February 2019 The 2010 MenAfriVac® vaccine launch in Burkina Faso PATH/Gabe Bienczycki Contents 1. Overview ...................................................................................................................................................... 3 1.1 Purpose ............................................................................................................................................ 3 1.2 Scope ............................................................................................................................................... 3 1.3 Content ............................................................................................................................................ 3 2. Global and regional burden of meningitis ................................................................................................... 4 2.1. Epidemiology ................................................................................................................................... 4 2.2. Modelling the burden of meningitis ..................................................................................................... 6 2.3. Global mortality and incidence ............................................................................................................ 6 2.4. Regional mortality and incidence ....................................................................................................... 10 2.5. Complications and sequelae ............................................................................................................... 11 2.6. Monitoring roadmap progress from 2015 to 2030 ............................................................................ 12 3. Prevention and epidemic control .................................................................................................................. 14 3.1 Prevention: licensed vaccines and vaccines in clinical development ...................................................... 14 3.2 Prevention: vaccination programmes ..................................................................................................... 18 3.2.1 Recommended vaccination programmes (EPI, outbreaks) .............................................................. 18 3.2.2 Implementation status: global/regional ........................................................................................... 19 3.2.3 Barriers to implementation .............................................................................................................. 23 3.2.4 Gap analysis (programme implementation, R&D) ........................................................................... 24 3.3 Prevention: chemoprophylaxis ................................................................................................................ 25 3.3.1 Recommended practice .................................................................................................................... 25 3.3.2 Implementation status: global/regional ........................................................................................... 26 3.3.3 Barriers to implementation .............................................................................................................. 26 3.3.4 Gap analysis ...................................................................................................................................... 26 3.4 Epidemic control ...................................................................................................................................... 26 3.4.1 Recommended practice .................................................................................................................... 26 3.4.2 Implementation status ..................................................................................................................... 27 3.4.3 Barriers to implementation .............................................................................................................. 27 3.4.4 Gap analysis ...................................................................................................................................... 28 4. Diagnosis and Treatment ............................................................................................................................... 29 4.1 Diagnosis .................................................................................................................................................. 29 4.1.1 Laboratory tests ................................................................................................................................ 29 4.1.2 Recommended practice .................................................................................................................... 30 4.1.3 Implementation status: global/regional ........................................................................................... 32 4.1.4 Barriers to implementation .............................................................................................................. 32 4.1.5 Gap analysis ...................................................................................................................................... 32 4.2 Treatment ................................................................................................................................................ 33 4.2.1 Recommended practice .................................................................................................................... 33 4.2.2 Implementation status ..................................................................................................................... 36 4.2.3 Barriers to implementation .............................................................................................................. 36 4.2.4 Gap analysis ...................................................................................................................................... 36 5. Disease surveillance....................................................................................................................................... 36 5.1 Introduction ......................................................................................................................................... 37 5.2 Recommended surveillance practices ................................................................................................. 38 5.3 Implementation status: global/regional .............................................................................................. 39 5.4 Barriers to implementation ................................................................................................................. 40 5.5. Gap analysis ........................................................................................................................................ 40 6. Support and after-care for families and survivors ......................................................................................... 41 6.1 Introduction ................................................................................................................................... 41 6.2 Recommended practice: rehabilitation and psychosocial support ............................................... 41 1 Defeating meningitis by 2030: baseline situation analysis 6.3 Implementation status .................................................................................................................. 42 6.4 Barriers to implementation ........................................................................................................... 43 6.5 Gap analysis ................................................................................................................................... 44 7. Advocacy and information ........................................................................................................................ 46 7.1 Advocacy ............................................................................................................................................ 46 7.1.1 Introduction ...................................................................................................................................... 46 7.1.2 Recommended practice .................................................................................................................... 48 7.1.3 Status ................................................................................................................................................ 48 7.1.4 Barriers to implementation .............................................................................................................. 49 7.1.5 Gap analysis ...................................................................................................................................... 50 7.2 Information .............................................................................................................................................. 51 7.2.1 Introduction ...................................................................................................................................... 51 7.2.2 Recommended practice .................................................................................................................... 52 7.2.3 Implementation status .....................................................................................................................
Load more

Recommended publications
  • Melioidosis: a Clinical Model for Gram-Negative Sepsis
    J. Med. Microbiol. Ð Vol. 50 2001), 657±658 # 2001 The Pathological Society of Great Britain and Ireland ISSN 0022-2615 EDITORIAL Melioidosis: a clinical model for gram-negative sepsis The recently published study of recombinant human clinical sepsis model over the current heterogeneous activated protein C drotrecogin-á, Eli Lilly, Indiana- clinical trials. Our knowledge of melioidosis and its polis, IN, USA) in severe sepsis makes welcome causative organism, Burkholderia formerly Pseudomo- reading. At last a clinical trial of an augmentative nas) pseudomallei, has expanded considerably over the therapy in severe sepsis has managed to show a last 15 years. Melioidosis was originally described in mortality bene®t from the trial agent [1]. Most studies Myanmar then Burma) in 1911 and came to of augmentative treatments in serious sepsis have failed prominence during the Vietnam con¯ict, when French to show clear bene®t. Sepsis studies commonly involve and American soldiers became infected. It has been a syndrome caused by a myriad of organisms, occurring described in most countries of south-east Asia, in a very heterogeneous group of patients, who may be including the Peoples Republic of China and the Lao enrolled in one of several centres. This introduces PDR [5], but Thailand has the greatest reported disease multiple confounding factors. Agood model for clinical burden [6]. It is also endemic to northern Australia [7]. sepsis studies would ideally cause disease in a relatively Understanding of the epidemiology of the disease has homogeneous population, be acquired in a community been improved by the demonstration of two pheno- setting, present in large numbers to a single institution, typically similar but genetically distinct biotypes in the be caused by a single organism, and ordinarily result in environment [8], only one of which appears to be a substantial mortality rate.
    [Show full text]
  • Kellie ID Emergencies.Pptx
    4/24/11 ID Alert! recognizing rapidly fatal infections Susan M. Kellie, MD, MPH Professor of Medicine Division of Infectious Diseases, UNMSOM Hospital Epidemiologist UNMHSC and NMVAHCS Fever and…. Rash and altered mental status Rash Muscle pain Lymphadenopathy Hypotension Shortness of breath Recent travel Abdominal pain and diarrhea Case 1. The cross-country trucker A 30 year-old trucker driving from Oklahoma to California is hospitalized in Deming with fever and headache He is treated with broad-spectrum antibiotics, but deteriorates with obtundation, low platelet count, and a centrifugal petechial rash and is transferred to UNMH 1 4/24/11 What is your diagnosis? What is the differential diagnosis of fever and headache with petechial rash? (in the US) Tickborne rickettsioses ◦ RMSF Bacteria ◦ Neisseria meningitidis Key diagnosis in this case: “doxycycline deficiency” Key vector-borne rickettsioses treated with doxycycline: RMSF-case-fatality 5-10% ◦ Fever, nausea, vomiting, myalgia, anorexia and headache ◦ Maculopapular rash progresses to petechial after 2-4 days of fever ◦ Occasionally without rash Human granulocytotropic anaplasmosis (HGA): case-fatality<1% Human monocytotropic ehrlichiosis (HME): case fatality 2-3% 2 4/24/11 Lab clues in rickettsioses The total white blood cell (WBC) count is typicallynormal in patients with RMSF, but increased numbers of immature bands are generally observed. Thrombocytopenia, mild elevations in hepatic transaminases, and hyponatremia might be observed with RMSF whereas leukopenia
    [Show full text]
  • Pearls: Infectious Diseases
    Pearls: Infectious Diseases Karen L. Roos, M.D.1 ABSTRACT Neurologists have a great deal of knowledge of the classic signs of central nervous system infectious diseases. After years of taking care of patients with infectious diseases, several symptoms, signs, and cerebrospinal fluid abnormalities have been identified that are helpful time and time again in determining the etiological agent. These lessons, learned at the bedside, are reviewed in this article. KEYWORDS: Herpes simplex virus, Lyme disease, meningitis, viral encephalitis CLINICAL MANIFESTATIONS does not have an altered level of consciousness, sei- zures, or focal neurologic deficits. Although the ‘‘classic triad’’ of bacterial meningitis is The rash of a viral exanthema typically involves the fever, headache, and nuchal rigidity, vomiting is a face and chest first then spreads to the arms and legs. common early symptom. Suspect bacterial meningitis This can be an important clue in the patient with in the patient with fever, headache, lethargy, and headache, fever, and stiff neck that the meningitis is vomiting (without diarrhea). Patients may also com- due to echovirus or coxsackievirus. plain of photophobia. An altered level of conscious- Suspect tuberculous meningitis in the patient with ness that begins with lethargy and progresses to stupor either several weeks of headache, fever, and night during the emergency evaluation of the patient is sweats or a fulminant presentation with fever, altered characteristic of bacterial meningitis. mental status, and focal neurologic deficits. Fever (temperature 388C[100.48F]) is present in An Ixodes tick must be attached to the skin for at least 84% of adults with bacterial meningitis and in 80 to 24 hours to transmit infection with the spirochete 1–3 94% of children with bacterial meningitis.
    [Show full text]
  • Health: Epidemiology Subchapter 41A
    CHAPTER 41 – HEALTH: EPIDEMIOLOGY SUBCHAPTER 41A – COMMUNICABLE DISEASE CONTROL SECTION .0100 – REPORTING OF COMMUNICABLE DISEASES 10A NCAC 41A .0101 REPORTABLE DISEASES AND CONDITIONS (a) The following named diseases and conditions are declared to be dangerous to the public health and are hereby made reportable within the time period specified after the disease or condition is reasonably suspected to exist: (1) acquired immune deficiency syndrome (AIDS) - 24 hours; (2) anthrax - immediately; (3) botulism - immediately; (4) brucellosis - 7 days; (5) campylobacter infection - 24 hours; (6) chancroid - 24 hours; (7) chikungunya virus infection - 24 hours; (8) chlamydial infection (laboratory confirmed) - 7 days; (9) cholera - 24 hours; (10) Creutzfeldt-Jakob disease - 7 days; (11) cryptosporidiosis - 24 hours; (12) cyclosporiasis - 24 hours; (13) dengue - 7 days; (14) diphtheria - 24 hours; (15) Escherichia coli, shiga toxin-producing - 24 hours; (16) ehrlichiosis - 7 days; (17) encephalitis, arboviral - 7 days; (18) foodborne disease, including Clostridium perfringens, staphylococcal, Bacillus cereus, and other and unknown causes - 24 hours; (19) gonorrhea - 24 hours; (20) granuloma inguinale - 24 hours; (21) Haemophilus influenzae, invasive disease - 24 hours; (22) Hantavirus infection - 7 days; (23) Hemolytic-uremic syndrome – 24 hours; (24) Hemorrhagic fever virus infection - immediately; (25) hepatitis A - 24 hours; (26) hepatitis B - 24 hours; (27) hepatitis B carriage - 7 days; (28) hepatitis C, acute - 7 days; (29) human immunodeficiency
    [Show full text]
  • Heaven's Wager, Thunder of Heaven, and When Heaven Weeps PDF by Ted Dekker PDF Online Free
    Download The Heaven Trilogy: Heaven's Wager, Thunder of Heaven, and When Heaven Weeps PDF by Ted Dekker PDF Online free Download The Heaven Trilogy: Heaven's Wager, Thunder of Heaven, and When Heaven Weeps PDF by Ted Dekker PDF Online free The Heaven Trilogy: Heaven's Wager, Thunder of Heaven, and When Heaven Weeps He is known for stories that combine adrenaline-laced plots with incredible confrontations between good and evil. Twitter @TedDekker, facebook/#!/teddekker . He is known for stories that combine adrenaline-laced plots with incredible confrontations between good and evil. Ted Dekker is the New York Times best-selling author of more than 25 novels. He lives in Texas with his wife and children. About the AuthorTed Dekker is the New York Times best-se The book The Heaven Trilogy: Heaven's Wager, Thunder of Heaven, and When Heaven Weeps written by Ted Dekker consist of 1072 pages. It published on 2014-07-08. This book available on paperback format but you can read it online or even download it from our website. Just follow the simple step. 1 / 5 Download The Heaven Trilogy: Heaven's Wager, Thunder of Heaven, and When Heaven Weeps PDF by Ted Dekker PDF Online free Read [Ted Dekker Book] The Heaven Trilogy: Heaven's Wager, Thunder of Heaven, and When Heaven Weeps Online PDF free The Violent Decade: A Foreign Correspondent in Europe and the Middle East, 1935-1945 BEAUTY FLASH YOU Rule! Take Charge of Your Health and Life: A Healthy Lifestyle Guide for Teens Nanosciences: The Invisible Revolution Knights of the Blood (Knights of Blood)
    [Show full text]
  • One Vaccine, Two Diseases, Three Lessons
    Wednesday, 2 October 2019 One vaccine, two diseases, three lessons Helen Petousis-Harris, PhD Senior Lecturer, Vaccinology Dept General Practice and Primary Health Care Overview Virtues of an outer Kissing cousins, two Serendipity and membrane vesicle vaccine? divergent diseases opportunity Wednesday, October 2, 2019 • Most meningococcal vaccines based on polysaccharide antigens (groups A, C, W135, Y) • Meningococcal Group B oligosaccharides cross react with fetal neuro tissue – not suitable vaccine antigen • Meningococcal Group B vaccine approaches needed to be 3 different – non PS-Conjugate Solution – outer membrane vesicles There are many other antigenic structures aside from PS Outer-membrane vesicles generate mainly strain specific responses against PorA which is highly variable across strains Developed in 1980’s and used Cuba and Norway 4 2/10/2019 Tan LKK, Carlone GM, Borrow R. Advances in the Development of Vaccines against Neisseria meningitidis. New England Journal of Medicine. 2010;362:1511-20. Meet the family 80-90% homology in primary sequences High level of recombination 5 Muzzi, A., Mora, M., Pizza, M., Rappuoli, R., & Donati, C. (2013). Conservation of meningococcal antigens in the genus Neisseria. MBio, 4(3), e00163-13. What is gonorrhoea? 6 2/10/2019 How common is gonorrhoea? • Second most reported sexually transmitted disease in US (600,000 cases per annum) • In NZ ~3000 cases per annum (60-90 per 100,000) • To put in context – Invasive Pneumococal Disease pre-vaccine <2s ~100 per 100,000 – Meningococcal disease at its height 17 per 100,000 • Tairawhiti DHB 400 per 100,000 7 No correlate of protection and repeat infections • Natural infection with gonorrhoea does not induce a protective immune response.
    [Show full text]
  • 2017 Indiana Report of Infectious Diseases
    ANNUAL REPORT OF INFECTIOUS DISEASES 2017 INTRODUCTION Indiana Field Epidemiology Districts ................................................................................................ iv Indiana Population Estimates, 2017 ...........................................................................................v List of Reportable Diseases & Conditions in Indiana, 2017 ............................................................ vii FOODBORNE & WATERBORNE DISEASES & CONDITIONS ..................................................................... 1 Campylobacteriosis ............................................................................................................................ 3 Cryptosporidiosis ................................................................................................................................ 7 Escherichia coli, Shiga toxin-producing .......................................................................................... 11 Giardiasis ........................................................................................................................................... 15 Hepatitis A ........................................................................................................................................ 18 Legionellosis .................................................................................................................................... 21 Listeriosis ........................................................................................................................................
    [Show full text]
  • COMMUNICABLE DISEASES BULLETIN Centre for Disease Control
    THE NORTHERN TERRITORY NT COMMUNICABLE DISEASES BULLETIN Centre for Disease Control ISSN 1323-8612 Vol. 5, No 1, March 1998 Congratulations to all the heroic service providers and volunteers who cleaned up after the Katherine and Douglas Daly River floods and kept things going throughout. In the aftermath of the Katherine and Douglas Daly River floods The recent floods in Katherine and the Douglas Ross River virus since the floods. In addition, there Daly River region gave CDC the opportunity to has been no apparent increase in the number of assess and review disease control priorities in cases of hepatitis A (incubation period 15-50 days, disaster situations. While disasters and their public usually 30 days) although it is still under enhanced health consequences differ according to individual Contents circumstances, a number of important lessons for In the aftermath of the Katherine and Douglas Daly River disaster preparedness can be learned from the floods .................................................................................. 1 international and local literature on disasters (short The effect of conjugate Hib vaccines on the incidence of invasive Hib disease in the NT ....................................... 3 list overleaf). The main dangers in the acute post- Evidence associating measles viruses with Crohn’s disaster phase are injuries and acute exacerbations disease and autism inconclusive ......................................... 6 of chronic diseases such as diabetes, especially if Update on HIV and hepatitis C in the NT........................... 7 medical supplies run short. Non-communicable diseases update: No.4 ......................... 9 Death of a five year old from meningococcal disease Outbreaks of infectious disease after a disaster are in Darwin.......................................................................... 12 Lessons from a case of meningococcal eye disease .........
    [Show full text]
  • A77X AX Series
    Operation Manual / Bedienungsanleitung English / deutsch AX Series A3X / A5X / A7X / A8X / A77X A77X A7X A8X A5X A3X Safety Instructions Please read the following safety instructions before setting up your system. Keep the instructions for subsequent reference. Please heed the warnings and follow the instructions. Caution Risk of electrical shock Do not open Risque de shock electrique Ne pas ouvrier CAUTION: TO REDUCE THE RISK OF FIRE OR ELECTRIC SHOCK, DO NOT REMOVE BACK COVER OR ANY OTHER PART. NO USER-SERVICABLE PARTS INSIDE. DO NOT EXPOSE THIS EQUIPMENT TO RAIN OR MOISTURE. REFER SERVICING TO QUALIFIED PERSONNEL. Caution: To reduce the risk of electric shock, do not open the loudspeaker. There are no user-serviceable parts inside. Refer servicing to qualified ser- vice personnel. This product, as well as all attached extension cords, must be terminated with an earth ground three-conductor AC mains power cord like the one supplied with the product. To prevent shock hazard, all three components must always be used. Never replace any fuse with a value or type other than those specified. Never bypass any fuse. Check if the specified voltage matches the voltage of the power supply you use. If this is not the case do not connect the loudspeakers to a power source! Please contact your local dealer or national distributor. Always switch off your entire system before connecting or disconnecting any cables, or when cleaning any components. To completely disconnect from AC mains, disconnect the power supply from the AC receptacle. The monitor should be installed near the socket outlet and disconnection of the device should be easily accessible.
    [Show full text]
  • Infectious Diseases Weekly Report Tokyo
    Infectious Diseases Weekly Report Tokyo Metropolitan Infectious Disease Surveillance Center 3 June 2021 / Number 21 ( 5/24 ~ 5/30 ) Surveillance System in Tokyo, Japan The infectious diseases which all physicians must report All physicians must report to health centers the incidence of the diseases which are shown at page one. Health centers electronically report the individual cases to Tokyo Metropolitan Infectious Disease Surveillance Center. The infectious diseases required to be reported by the sentinels The numbers of patients who visit the sentinel clinics or hospitals during a week are reported to health centers in Tokyo. And they electronically report the numbers to Tokyo Metropolitan Infectious Disease Surveillance Center. We have about 500 sentinel clinics and hospitals in Tokyo. Tokyo Metropolitan Institute of Public Health TEL:81-3-3363-3213 FAX:81-3-5332-7365 e-mail:[email protected] URL:idsc.tokyo-eiken.go.jp/ Number of patients with the diseases which all physicians must report Tokyo Japan Category Diseases Cum Cum 18th 19th 20th 21st 21st 2021 2021 Ebola hemorrhagic fever Crimean-Congo hemorrhagic fever Smallpox I South American hemorrhagic fever Plague Marburg disease Lassa fever Acute poliomyelitis Tuberculosis 26 32 63 45 883 268 6,125 Diphtheria II Severe Acute Respiratory Syndrome(SARS) Middle East Respiratory Syndrome (MERS) Avian influenza H5N1 Avian influenza H7N9 Cholera Shigellosis 24 III Enterohemorrhagic Escherichia coli infection 22885349483 Typhoid fever Paratyphoid fever Hepatitis E 1441631226 West Nile
    [Show full text]
  • Illinois Register Department of Public Health Notice of Proposed Amendments Title 77
    ILLINOIS REGISTER DEPARTMENT OF PUBLIC HEALTH NOTICE OF PROPOSED AMENDMENTS TITLE 77: PUBLIC HEALTH CHAPTER I: DEPARTMENT OF PUBLIC HEALTH SUBCHAPTER k: COMMUNICABLE DISEASE CONTROL AND IMMUNIZATIONS PART 690 CONTROL OF COMMUNICABLE DISEASES CODE SUBPART A: GENERAL PROVISIONS Section 690.10 Definitions 690.20 Incorporated and Referenced Materials 690.30 General Procedures for the Control of Communicable Diseases SUBPART B: REPORTABLE DISEASES AND CONDITIONS Section 690.100 Diseases and Conditions 690.110 Diseases Repealed from This Part SUBPART C: REPORTING Section 690.200 Reporting SUBPART D: DETAILED PROCEDURES FOR THE CONTROL OF COMMUNICABLE DISEASES Section 690.290 Acquired Immunodeficiency Syndrome (AIDS) (Repealed) 690.295 Any Unusual Case of a Disease or Condition Caused by an Infectious Agent Not Listed in this Part that is of Urgent Public Health Significance (Reportable by telephone immediately (within three hours)) 690.300 Amebiasis (Reportable by mail, telephone, facsimile or electronically as soon as possible, within 7 days) (Repealed) 690.310 Animal Bites (Reportable by mail or telephone as soon as possible, within 7 days) (Repealed) 690.320 Anthrax (Reportable by telephone immediately, within three hours, upon initial clinical suspicion of the disease) 690.322 Arboviral Infections (Including, but Not Limited to, Chikungunya Fever, ILLINOIS REGISTER DEPARTMENT OF PUBLIC HEALTH NOTICE OF PROPOSED AMENDMENTS California Encephalitis, St. Louis Encephalitis, Dengue Fever and West Nile Virus) (Reportable by mail, telephone, facsimile
    [Show full text]
  • Celebrity Farmer to Grow Meningitis Awareness
    MENINGITIS NOW PRESS RELEASE MAY 30, 2014 Celebrity farmer to grow meningitis awareness ONE of the UK’s best-known farmers Adam Henson is pleased to grow awareness of a deadly disease after becoming a Meningitis Now celebrity ambassador. The rural TV presenter knows how devastating meningitis can be after his friends Rod and Anna Adlington, of Coventry, lost their three-year-old Barney to meningitis in 2005. Adam, co-director of Cotswold Farm Park near Stow-on-the-Wold, supported Meningitis Now’s Five Valleys Walk around the Cotswolds last year. He was also a guest when Their Royal Highnesses, The Earl and Countess of Wessex, a Meningitis Now patron, visited the charity’s Stroud headquarters in April. Adam, who has contributed to BBC Radio 4’s On Your Farm and Farming Today, was very impressed by the UK’s largest meningitis charity’s work, and delighted to be invited to become an ambassador. Conservationist Adam, who has also written for Countryfile magazine, said: “I’m amazed by the charity’s work to fund pioneering research, raise awareness and support survivors and their families – I had to help. “It’s my pleasure to become an ambassador and I look forward to helping as much as I can.” Meningitis Now chief executive Sue Davie added: “We’re thrilled to have Adam – such a popular and regarded personality – aiding our work.” For more information, visit www.MeningitisNow.org. ENDS Editors Notes: Photo Caption: Adam Henson a (Credit Clint Randall) – CELEB SUPPORT: Adam Henson meets Meningitis Now staff, from left, Kelly Archer, Emily Smith,
    [Show full text]